ATARA BIOTHERAPEUTICS, INC. Finance Lease, Right-of-Use Asset, Amortization
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Finance Lease, Right-of-Use Asset, Amortization of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $240.00K, a 74.97% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $959.00K, a 1.74% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $976.00K, a 11.93% increase from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $872.00K, a 257.38% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $240.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $240.00K 10-Q · filed 2025-11-12 | $480.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $240.00K 10-Q · filed 2026-08-12 | $480.00K derived: sum of 3 quarters · filed 2026-08-12 | $720.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $240.00K 10-Q · filed 2026-05-12 | $480.00K derived: sum of 2 quarters · filed 2026-05-12 | $720.00K derived: sum of 3 quarters · filed 2026-05-12 | $960.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $240.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $480.00K derived: sum of 2 quarters · filed 2026-03-16 | $720.00K derived: sum of 3 quarters · filed 2026-03-16 | $959.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $240.00K 10-Q · filed 2025-11-12 | $480.00K derived: sum of 2 quarters · filed 2025-11-12 | $719.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $240.00K 10-Q · filed 2025-08-11 | $480.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $240.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $976.00K 10-K · filed 2025-03-07 | |||
| 2022-12-31 | $264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $529.00K derived: sum of 2 quarters · filed 2024-03-28 | $815.00K derived: sum of 3 quarters · filed 2024-03-28 | $872.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $265.00K 10-Q · filed 2022-11-08 | $551.00K derived: sum of 2 quarters · filed 2022-11-08 | $608.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $286.00K 10-Q · filed 2022-08-08 | $343.00K 10-Q · filed 2022-08-08 | ||
| 2021-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $116.00K derived: sum of 2 quarters · filed 2023-02-08 | $179.00K derived: sum of 3 quarters · filed 2023-02-08 | $244.00K 10-K · filed 2023-02-08 |
| 2021-09-30 | $59.00K 10-Q · filed 2022-11-08 | $122.00K derived: sum of 2 quarters · filed 2022-11-08 | $187.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $63.00K 10-Q · filed 2022-08-08 | $128.00K 10-Q · filed 2022-08-08 | ||
| 2020-12-31 | $389.00K 10-K · filed 2023-02-08 | |||
| 2019-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $157.00K derived: sum of 2 quarters · filed 2022-02-28 | $241.00K derived: sum of 3 quarters · filed 2022-02-28 | $324.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $83.00K 10-Q · filed 2019-11-07 | $167.00K derived: sum of 2 quarters · filed 2019-11-07 | $250.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $84.00K 10-Q · filed 2019-08-08 | $167.00K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $83.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |